The report, released July 30, analyzed pharmacy program participants’ purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient’s analysts predicted a 4.18% drug price inflation rate for oncology medication in 2025, more than the predicted 3.81% overall drug price inflation rate.
The oncology medications that saw the biggest share of spending were:
- Keytruda (pembrolizumab): 3.28%
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 1.36%
- Opdivo (nivolumab): 1.24%
- Imfinzi (durvalumab): 0.61%
- Tecentriq (atezolizumab): 0.54%
- Blincyto (blinatumomab): 0.53%
- Jakafi (ruxolitinib phosphate): 0.50%
- Perjeta (pertuzumab): 0.48%
- Adcetris (brentuximab vedotin): 0.45%
- Tagrisso (osimertinib mesylate): 0.45%
The top oncology medications with the greatest change in spend were:
- Kisqali (ribociclib): 190% increase
- Padcev (enfortumab vedotin-efjv): 69% increase
- Blincyto (blinatumomab): 56% increase
- Imfinzi (durvalumab): 38% increase
- Darzalex Faspro (daratumumab-hyaluronidase-fihj): 17% increase
- Keytruda (pembrolizumab): 13% increase
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
